NOVOB Stock Overview
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 3/6 |
Past Performance | 6/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Novo Nordisk A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.86.71 |
52 Week High | kr.87.51 |
52 Week Low | kr.59.42 |
Beta | 0.19 |
1 Month Change | 0% |
3 Month Change | -0.92% |
1 Year Change | 45.72% |
3 Year Change | 175.26% |
5 Year Change | 278.02% |
Change since IPO | 74.29% |
Recent News & Updates
Recent updates
Shareholder Returns
NOVOB | CH Pharmaceuticals | CH Market | |
---|---|---|---|
7D | 0% | -0.1% | 0.8% |
1Y | 45.7% | -4.5% | 3.3% |
Return vs Industry: NOVOB exceeded the Swiss Pharmaceuticals industry which returned -9.5% over the past year.
Return vs Market: NOVOB exceeded the Swiss Market which returned -0.9% over the past year.
Price Volatility
NOVOB volatility | |
---|---|
NOVOB Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 3.1% |
Market Average Movement | 3.4% |
10% most volatile stocks in CH Market | 7.7% |
10% least volatile stocks in CH Market | 1.8% |
Stable Share Price: NOVOB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NOVOB's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1923 | 61,412 | Lars Jorgensen | https://www.novonordisk.com |
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases.
Novo Nordisk A/S Fundamentals Summary
NOVOB fundamental statistics | |
---|---|
Market cap | CHF388.31b |
Earnings (TTM) | CHF9.54b |
Revenue (TTM) | CHF27.18b |
40.7x
P/E Ratio14.3x
P/S RatioIs NOVOB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NOVOB income statement (TTM) | |
---|---|
Revenue | kr.214.49b |
Cost of Revenue | kr.34.01b |
Gross Profit | kr.180.48b |
Other Expenses | kr.105.17b |
Earnings | kr.75.31b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Jan 31, 2024
Earnings per share (EPS) | 16.89 |
Gross Margin | 84.14% |
Net Profit Margin | 35.11% |
Debt/Equity Ratio | 28.5% |
How did NOVOB perform over the long term?
See historical performance and comparison